



ReoPro[®] (abciximab) – Drug Shortage

- The [drug shortage](#) of Janssen Biotech's [ReoPro \(abciximab\)](#) is ongoing. Reopro has been unavailable for at least 90 days due to a long-term shortage of an ingredient from a third party manufacturer. Janssen Biotech does not have an estimated time frame as to when the shortage will resolve
- Reopro is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications: in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours.

Product Description	NDC #
ReoPro (abciximab) 2 mg/mL, 5 mL vial	57894-200-01



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.